Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LEUPROLIDE Cause Prostate cancer metastatic? 747 Reports in FDA Database

Prostate Health & Male Vitality — Naturally

ProstaVive: better flow, better sleep, better energy. 180-day guarantee.

Learn More

According to the FDA Adverse Event Reporting System (FAERS), 747 reports of Prostate cancer metastatic have been filed in association with LEUPROLIDE (Fensolvi). This represents 1.1% of all adverse event reports for LEUPROLIDE.

747
Reports of Prostate cancer metastatic with LEUPROLIDE
1.1%
of all LEUPROLIDE reports
310
Deaths
187
Hospitalizations

How Dangerous Is Prostate cancer metastatic From LEUPROLIDE?

Of the 747 reports, 310 (41.5%) resulted in death, 187 (25.0%) required hospitalization, and 27 (3.6%) were considered life-threatening.

Is Prostate cancer metastatic Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LEUPROLIDE. However, 747 reports have been filed with the FAERS database.

What Other Side Effects Does LEUPROLIDE Cause?

Hot flush (9,146) Death (8,772) Intercepted product preparation error (8,621) Syringe issue (7,847) Device leakage (5,861) Wrong technique in product usage process (5,062) Fatigue (4,805) Injection site pain (4,678) Prostatic specific antigen increased (2,432) Asthenia (2,176)

What Other Drugs Cause Prostate cancer metastatic?

ABIRATERONE (488) DOCETAXEL (198) ENZALUTAMIDE (165) DENOSUMAB (144) PREDNISONE (139) RADIUM RA-223 DICHLORIDE (120) CABAZITAXEL (74) BICALUTAMIDE (72) ZOLEDRONIC ACID (71) DEXAMETHASONE (59)

Which LEUPROLIDE Alternatives Have Lower Prostate cancer metastatic Risk?

LEUPROLIDE vs LEVALBUTEROL LEUPROLIDE vs LEVAMISOLE LEUPROLIDE vs LEVAQUIN LEUPROLIDE vs LEVEMIR LEUPROLIDE vs LEVETIRACETAM

Related Pages

LEUPROLIDE Full Profile All Prostate cancer metastatic Reports All Drugs Causing Prostate cancer metastatic LEUPROLIDE Demographics